Format

Send to

Choose Destination
J Cell Biochem. 2013 Jul;114(7):1457-63. doi: 10.1002/jcb.24487.

MiR-199b-5p targets HER2 in breast cancer cells.

Author information

1
Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.

Abstract

HER2 (ErbB2) has been reported to be overexpressed in 20-30% of breast cancer and confers poor survival because of high proliferation and metastasis rates. MicroRNAs are small noncoding RNAs that are responsible for the post-transcriptional regulation of target genes. We found miR-199b-5p inhibited HER2 expression by direct targeting its 3'-untranslated region (3'UTR) in breast cancer cells. In addition, miR-199b-5p inhibited HER2 downstream signaling by ERK1/2 and AKT pathways in breast cancer cells. Besides, transwell migration, wound healing, and clonogenicity were obviously inhibited by overexpression of miR-199b-5p in HER2-positive breast cancer cells. We also found that miR-199b-5p could enhance the suppression of trastuzumab on cell migration and clonogenicity. These results suggest that miR-199b-5p may have the potential to be a novel important alternative therapeutic target for HER2-positive breast cancer.

PMID:
23296799
DOI:
10.1002/jcb.24487
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center